LandmarkRCT

MIDEX/PRODEX

Dexmedetomidine vs Midazolam or Propofol for Sedation During Prolonged Mechanical Ventilation

JAMA, 2012 · Two multicenter, randomized, double-blind noninferiority trials

Clinical question

Is dexmedetomidine noninferior to midazolam or propofol for prolonged light-to-moderate ICU sedation?

Population: Mechanically ventilated ICU adults requiring prolonged light-to-moderate sedation.
Inclusion criteria: Adult ICU patient
Mechanical ventilation
Need for prolonged light-to-moderate sedation
Intervention: Dexmedetomidine-based sedation.
Comparator: Midazolam (MIDEX) or propofol (PRODEX).
Primary outcome: Time at target sedation without rescue medication.
Secondary outcomes: Duration of mechanical ventilation
Patient interaction
Adverse effects
Result: Dexmedetomidine was noninferior for maintaining target sedation and improved some interaction/ventilation outcomes, with more bradycardia and hypotension.

What the trial found

Dexmedetomidine was an effective alternative to midazolam and propofol for prolonged light-to-moderate sedation.

Current guideline position

Agent selection should reflect sedation target, delirium risk, hemodynamics, and current PADIS recommendations.

Clinical interpretation

Supports dexmedetomidine as a useful light-sedation agent rather than implying universal superiority over propofol for every ICU patient.

Limitations

Industry-sponsored trials and selected light-to-moderate sedation population limit generalizability to deep sedation.

High certainty

Clinical Context & Relevant Topics (1)

Disease Reference

Analgesia-first sedation, light sedation targets, ABCDEF bundle, spontaneous breathing trials, and non-pharmacologic delirium mitigation.